Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GAA | P10253 | 2/20 | 0.34 |
| ▸ | PKM | P14618 | 1/20 | 0.34 |
| ▸ | HTT | P42858 | 1/20 | 0.34 |
| ▸ | HMGCR | P04035 | 2/20 | 0.32 |
| ▸ | MEN1 | O00255 | 1/20 | 0.32 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.32 |
| ▸ | MAOB | P27338 | 2/20 | 0.31 |
| ▸ | MAOA | P21397 | 1/20 | 0.31 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.31 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.31 |
| ▸ | MAPT | P10636 | 1/20 | 0.30 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1695282 | 0.84 | HMGCR (0.36) | GAAPKMHTTHMGCRMEN1 | |
| SCHEMBL1788650 | 0.80 | ALDH1A1 (0.33) | GAAPKMHTTMEN1KMT2A | |
| SCHEMBL1695280 | 0.80 | HMGCR (0.37) | GAAPKMHTTHMGCRMEN1 | |
| SCHEMBL27974159 | 0.77 | GAA (0.39) | GAAPKMHTTHMGCRMEN1 | |
| SCHEMBL6359442 | 0.75 | GAA (0.36) | GAAPKMHTTHMGCRKMT2A | |
| SCHEMBL4830860 | 0.73 | HMGCR (0.47) | GAAPKMHTTHMGCRMEN1 | |
| SCHEMBL6872532 | 0.72 | NR5A2 (0.37) | GAAHTTALDH1A1 | |
| SCHEMBL15023930 | 0.72 | GAA (0.32) | GAAPKMHTTMEN1KMT2A | |
| SCHEMBL38994 | 0.72 | ALDH1A1 (0.37) | GAAHTTALDH1A1 | |
| SCHEMBL7759198 | 0.72 | GAA (0.37) | GAAPKMHTTHMGCRMEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6919454-B2 | Biphenyl-substituted triazines | CIBA SPECIALTY CHEMICALS CORP. (US) | 2005-07-19 | — | — | US | disclosed |
| US-20050019281-A1 | Biphenyl-substituted triazines | FLETCHER IAN JOHN (CH) | 2005-01-27 | — | — | US | disclosed |
| US-5955517-A | POLAR ADSORPTIVE ORGANIC FIBERS OR PARTICLES ONTO WHICH IS BOUND POLAR ANTISTATIC AGENT COMPRISING MIXTURE OF POLYOXYALKYLENE AND SALT OF PROTIC ACID | CIBA SPECIALTY CHEMICALS CORPORATION (US) | 1999-09-21 | — | — | US | disclosed |
| US-5688995-A | SUNSCREEN AGENTS | CIBA-GEIGY CORPORATION (US) | 1997-11-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050019281-A1 | Biphenyl-substituted triazines | TYR, AHR, CUTA | GAA 2843/4885PKM 4049/4885HTT 1447/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.